ILT-3 Inhibitors
Chemical inhibitors of ILT-3 can affect its signaling role through various mechanisms of action that target different cellular pathways. Cyclosporin A, FK506 (Tacrolimus), Ascomycin, and Mycophenolic acid act on the immune system by inhibiting calcineurin or enzymes crucial for nucleotide synthesis, leading to a reduction in T-cell activation. The reduced activity of T cells translates into lesser engagement of ILT-3 with its ligands, effectively diminishing its signaling capabilities. This is due to ILT-3's role in immune modulation, which requires interactions with other cells of the immune system that are curtailed when these cells are in a suppressed state. Similarly, Rapamycin (Sirolimus) and Leflunomide target mTOR and dihydroorotate dehydrogenase, respectively, and by doing so, they limit the proliferation and response of T cells. The dampened response of T cells restricts the functional activity of ILT-3, as the protein's role is closely tied to the behavior of these cells.
Furthermore, corticosteroids like Dexamethasone and Hydrocortisone indirectly inhibit ILT-3 by inducing the expression of anti-inflammatory proteins and suppressing the immune response. This broad suppression of immune activity can lead to a reduction in the functional pathways where ILT-3 is active, as its engagement is often predicated on the broader state of immune cell activation. PD98059, SB203580, and SP600125 are inhibitors of specific kinases within the MAPK pathway, such as MEK, p38, and JNK. These kinases are involved in the regulation of immune responses, including cytokine production and cell differentiation. The inhibition of these kinases can lead to a reduced activation of immune cells, which in turn, can lead to a lessened functional activity of ILT-3. Wortmannin acts upon the PI3K pathway, which is critical for cell survival and activation. By impeding PI3K, Wortmannin affects T-cell activation, which can reduce the immune cell responses that would otherwise engage ILT-3 in its regulatory role.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $62.00 $90.00 $299.00 $475.00 $1015.00 $2099.00 | 69 | |
Cyclosporin A, an immunosuppressant, inhibits calcineurin which is crucial for T-cell activation. By inhibiting T-cell activation, Cyclosporin A can reduce the immune response, potentially diminishing the ligand availability for ILT-3, thus functionally inhibiting its signaling role. | ||||||
FK-506 | 104987-11-3 | sc-24649 sc-24649A | 5 mg 10 mg | $76.00 $148.00 | 9 | |
FK506 binds to FKBP12, forming a complex that inhibits calcineurin, thereby suppressing T-cell activation. This suppression is likely to lower the engagement of ILT-3 with its ligands, indirectly inhibiting ILT-3's function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin forms a complex with FKBP12, targeting mTOR, a key regulator of cell proliferation and survival. By inhibiting mTOR, Rapamycin can attenuate responses that indirectly require ILT-3 for full activation of certain immune cells. | ||||||
Ascomycin | 104987-12-4 | sc-207303B sc-207303 sc-207303A | 1 mg 5 mg 25 mg | $36.00 $173.00 $316.00 | ||
Ascomycin, similar to FK506, binds to FKBP12 and inhibits calcineurin, leading to suppressed T-cell activation. This would decrease the activation of pathways that may rely on ILT-3 signaling. | ||||||
Dexamethasone | 50-02-2 | sc-29059 sc-29059B sc-29059A | 100 mg 1 g 5 g | $76.00 $82.00 $367.00 | 36 | |
Dexamethasone is a corticosteroid that can suppress the immune response by inducing the expression of anti-inflammatory proteins. This suppression could reduce the activation of pathways where ILT-3 is involved. | ||||||
Hydrocortisone | 50-23-7 | sc-300810 | 5 g | $100.00 | 6 | |
Hydrocortisone is a corticosteroid with anti-inflammatory effects that can lead to the suppression of immune cell activation, thereby possibly reducing the functional activity of ILT-3. | ||||||
Mycophenolic acid | 24280-93-1 | sc-200110 sc-200110A | 100 mg 500 mg | $68.00 $261.00 | 8 | |
Mycophenolic acid inhibits inosine monophosphate dehydrogenase, leading to the depletion of guanosine nucleotides and subsequent inhibition of T and B cell proliferation, which may reduce the functional engagement of ILT-3. | ||||||
Leflunomide | 75706-12-6 | sc-202209 sc-202209A | 10 mg 50 mg | $20.00 $81.00 | 5 | |
Leflunomide inhibits dihydroorotate dehydrogenase, which is necessary for pyrimidine synthesis. This inhibition can result in reduced proliferation of T cells, thereby indirectly inhibiting ILT-3 function due to reduced T cell interactions. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of MEK, which is part of the MAPK/ERK pathway. By inhibiting this pathway, PD98059 can lead to reduced immune cell activation and indirectly inhibit the functional activity of ILT-3. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 selectively inhibits p38 MAP kinase, which plays a role in cytokine production and T-cell differentiation. Inhibiting p38 MAP kinase can indirectly reduce the functional activity of ILT-3. | ||||||